259 related articles for article (PubMed ID: 28861639)
1. Repositioning of proton pump inhibitors in cancer therapy.
Lu ZN; Tian B; Guo XL
Cancer Chemother Pharmacol; 2017 Nov; 80(5):925-937. PubMed ID: 28861639
[TBL] [Abstract][Full Text] [Related]
2. Microenvironment acidity as a major determinant of tumor chemoresistance: Proton pump inhibitors (PPIs) as a novel therapeutic approach.
Taylor S; Spugnini EP; Assaraf YG; Azzarito T; Rauch C; Fais S
Drug Resist Updat; 2015 Nov; 23():69-78. PubMed ID: 26341193
[TBL] [Abstract][Full Text] [Related]
3. Proton pump inhibitor-induced tumour cell death by inhibition of a detoxification mechanism.
Fais S
J Intern Med; 2010 May; 267(5):515-25. PubMed ID: 20433578
[TBL] [Abstract][Full Text] [Related]
4. Drug repurposing for anticancer therapies. A lesson from proton pump inhibitors.
Spugnini EP; Fais S
Expert Opin Ther Pat; 2020 Jan; 30(1):15-25. PubMed ID: 31847622
[No Abstract] [Full Text] [Related]
5. Proton pump inhibitors may reduce tumour resistance.
De Milito A; Fais S
Expert Opin Pharmacother; 2005 Jun; 6(7):1049-54. PubMed ID: 15957961
[TBL] [Abstract][Full Text] [Related]
6. Tumor acidity, chemoresistance and proton pump inhibitors.
De Milito A; Fais S
Future Oncol; 2005 Dec; 1(6):779-86. PubMed ID: 16556057
[TBL] [Abstract][Full Text] [Related]
7. A nonmainstream approach against cancer.
Fais S
J Enzyme Inhib Med Chem; 2016 Dec; 31(6):882-9. PubMed ID: 26972280
[TBL] [Abstract][Full Text] [Related]
8. Drug-repositioning opportunities for cancer therapy: novel molecular targets for known compounds.
Würth R; Thellung S; Bajetto A; Mazzanti M; Florio T; Barbieri F
Drug Discov Today; 2016 Jan; 21(1):190-199. PubMed ID: 26456577
[TBL] [Abstract][Full Text] [Related]
9. Drug Repositioning of Proton Pump Inhibitors for Enhanced Efficacy and Safety of Cancer Chemotherapy.
Ikemura K; Hiramatsu S; Okuda M
Front Pharmacol; 2017; 8():911. PubMed ID: 29311921
[TBL] [Abstract][Full Text] [Related]
10. Role of proton pump inhibitors in preventing hypergastrinemia-associated carcinogenesis and in antagonizing the trophic effect of gastrin.
Han YM; Park JM; Kangwan N; Jeong M; Lee S; Cho JY; Ko WJ; Hahm KB
J Physiol Pharmacol; 2015 Apr; 66(2):159-67. PubMed ID: 25903947
[TBL] [Abstract][Full Text] [Related]
11. Proton pump inhibitors for the treatment of cancer in companion animals.
Walsh M; Fais S; Spugnini EP; Harguindey S; Abu Izneid T; Scacco L; Williams P; Allegrucci C; Rauch C; Omran Z
J Exp Clin Cancer Res; 2015 Sep; 34(1):93. PubMed ID: 26337905
[TBL] [Abstract][Full Text] [Related]
12. Proton pump inhibitors enhance chemosensitivity, promote apoptosis, and suppress migration of breast cancer cells.
Ihraiz WG; Ahram M; Bardaweel SK
Acta Pharm; 2020 Jun; 70(2):179-190. PubMed ID: 31955147
[TBL] [Abstract][Full Text] [Related]
13. Proton pump inhibitors while belonging to the same family of generic drugs show different anti-tumor effect.
Lugini L; Federici C; Borghi M; Azzarito T; Marino ML; Cesolini A; Spugnini EP; Fais S
J Enzyme Inhib Med Chem; 2016 Aug; 31(4):538-45. PubMed ID: 26018420
[TBL] [Abstract][Full Text] [Related]
14. Manipulating tumor acidification as a cancer treatment strategy.
McCarty MF; Whitaker J
Altern Med Rev; 2010 Sep; 15(3):264-72. PubMed ID: 21155627
[TBL] [Abstract][Full Text] [Related]
15. Repositioning proton pump inhibitors as anticancer drugs by targeting the thioesterase domain of human fatty acid synthase.
Fako VE; Wu X; Pflug B; Liu JY; Zhang JT
J Med Chem; 2015 Jan; 58(2):778-84. PubMed ID: 25513712
[TBL] [Abstract][Full Text] [Related]
16. Management of NSAID-induced gastrointestinal toxicity: focus on proton pump inhibitors.
Lazzaroni M; Porro GB
Drugs; 2009; 69(1):51-69. PubMed ID: 19192936
[TBL] [Abstract][Full Text] [Related]
17. A rationale for the use of proton pump inhibitors as antineoplastic agents.
De Milito A; Marino ML; Fais S
Curr Pharm Des; 2012; 18(10):1395-406. PubMed ID: 22360553
[TBL] [Abstract][Full Text] [Related]
18. Proton pump inhibitor pantoprazole inhibits the proliferation, self‑renewal and chemoresistance of gastric cancer stem cells via the EMT/β‑catenin pathways.
Feng S; Zheng Z; Feng L; Yang L; Chen Z; Lin Y; Gao Y; Chen Y
Oncol Rep; 2016 Dec; 36(6):3207-3214. PubMed ID: 27748935
[TBL] [Abstract][Full Text] [Related]
19. Effects and mechanisms of proton pump inhibitors as a novel chemosensitizer on human gastric adenocarcinoma (SGC7901) cells.
Chen M; Zou X; Luo H; Cao J; Zhang X; Zhang B; Liu W
Cell Biol Int; 2009 Sep; 33(9):1008-19. PubMed ID: 19501661
[TBL] [Abstract][Full Text] [Related]
20. Proton pump inhibitor selectively suppresses proliferation and restores the chemosensitivity of gastric cancer cells by inhibiting STAT3 signaling pathway.
Huang S; Chen M; Ding X; Zhang X; Zou X
Int Immunopharmacol; 2013 Nov; 17(3):585-92. PubMed ID: 23973653
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
